Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

757 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The role of anti-thymocyte globulin in allogeneic stem cell transplantation (HSCT) from HLA-matched unrelated donors (MUD) for secondary AML in remission: a study from the ALWP /EBMT.
Nagler A, Labopin M, Kröger N, Schroeder T, Gedde-Dahl T, Eder M, Franke GN, Blau IW, Salmenniemi U, Socie G, Schetelig J, Stelljes M, Ciceri F, Mohty M. Nagler A, et al. Among authors: eder m. Bone Marrow Transplant. 2023 Dec;58(12):1339-1347. doi: 10.1038/s41409-023-02095-0. Epub 2023 Sep 2. Bone Marrow Transplant. 2023. PMID: 37660157
Impact of chronic graft-versus-host-disease on intensive care outcome in allogeneic hematopoietic stem cell recipients.
Lueck C, Tzalavras A, Wohlfarth P, Meedt E, Kiehl M, Turki AT, Hoeper MM, Eder M, Cserna J, Buchtele N, Wolff D, Schellongowski P, Beutel G, Liebregts T. Lueck C, et al. Among authors: eder m. Bone Marrow Transplant. 2023 Mar;58(3):303-310. doi: 10.1038/s41409-022-01875-4. Epub 2022 Dec 10. Bone Marrow Transplant. 2023. PMID: 36496524 Free PMC article.
Comparison of fludarabine/melphalan (FluMel) with fludarabine/melphalan/BCNU or thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transplantation - a registry study on behalf of the EBMT Acute Leukemia Working Party.
Duque-Afonso J, Finke J, Ngoya M, Galimard JE, Craddock C, Raj K, Bloor A, Nicholson E, Eder M, Kim O, Valerius T, Snowden JA, Tholouli E, Crawley C, Collin M, Wilson KMO, Gadisseur A, Protheroe R, Wagner-Drouet EM, Savani BN, Spyridonidis A, Ciceri F, Nagler A, Mohty M. Duque-Afonso J, et al. Among authors: eder m. Bone Marrow Transplant. 2024 Feb;59(2):247-254. doi: 10.1038/s41409-023-02150-w. Epub 2023 Dec 2. Bone Marrow Transplant. 2024. PMID: 38040842 Free PMC article.
The impact of pre-transplantation diabetes and obesity on acute graft-versus-host disease, relapse and death after allogeneic hematopoietic cell transplantation: a study from the EBMT Transplant Complications Working Party.
Gjærde LK, Ruutu T, Peczynski C, Boreland W, Kröger N, Blaise D, Schroeder T, Peffault de Latour R, Gedde-Dahl T, Kulagin A, Sengeløv H, Yakoub-Agha I, Finke J, Eder M, Basak G, Moiseev I, Schoemans H, Koenecke C, Penack O, Perić Z. Gjærde LK, et al. Among authors: eder m. Bone Marrow Transplant. 2024 Feb;59(2):255-263. doi: 10.1038/s41409-023-02154-6. Epub 2023 Dec 7. Bone Marrow Transplant. 2024. PMID: 38062242 Free PMC article.
Allogeneic haematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for lymphoma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT.
Nabergoj M, Eikema DJ, Koster L, Platzbecker U, Sockel K, Finke J, Kröger N, Forcade E, Nagler A, Eder M, Tischer J, Broers AEC, Kuball J, Wilson KMO, Hunault-Berger M, Collin M, Russo D, Corral LL, Helbig G, Mussetti A, Scheid C, Gurnari C, Raj K, Drozd-Sokolowska J, Yakoub-Agha I, Robin M, McLornan DP. Nabergoj M, et al. Among authors: eder m. Bone Marrow Transplant. 2024 Mar;59(3):395-402. doi: 10.1038/s41409-023-02193-z. Epub 2024 Jan 9. Bone Marrow Transplant. 2024. PMID: 38195984
The graft-versus-leukemia effect of prophylactic donor lymphocyte infusions after allogeneic stem cell transplantation is equally effective in relapse prevention but safer compared to spontaneous graft-versus-host disease.
Stadler M, Hambach L, Dammann E, Diedrich H, Kamal H, Hamwi I, Schultze-Florey C, Varvenne M, Ehrlich S, Buchholz S, Koenecke C, Beutel G, Weissinger EM, Krauter J, Eder M, Hertenstein B, Ganser A. Stadler M, et al. Among authors: eder m. Ann Hematol. 2023 Sep;102(9):2529-2542. doi: 10.1007/s00277-023-05276-5. Epub 2023 Jul 25. Ann Hematol. 2023. PMID: 37490114 Free PMC article.
MRD as Biomarker for Response to Donor Lymphocyte Infusion after Allogeneic Hematopoietic Cell Transplantation in Patients with AML.
Teich K, Stadler M, Gabdoulline R, Kandarp J, Wienecke C, Heida B, Klement P, Büttner K, Venturini L, Wichmann M, Puppe W, Schultze-Florey C, Koenecke C, Beutel G, Eder M, Ganser A, Heuser M, Thol F. Teich K, et al. Among authors: eder m. Cancers (Basel). 2023 Aug 1;15(15):3911. doi: 10.3390/cancers15153911. Cancers (Basel). 2023. PMID: 37568726 Free PMC article.
Spectral flow cytometry cluster analysis of therapeutic donor lymphocyte infusions identifies T cell subsets associated with outcome in patients with AML relapse.
Odak I, Sikora R, Riemann L, Bayir LM, Beck M, Drenker M, Xiao Y, Schneider J, Dammann E, Stadler M, Eder M, Ganser A, Förster R, Koenecke C, Schultze-Florey CR. Odak I, et al. Among authors: eder m. Front Immunol. 2022 Oct 5;13:999163. doi: 10.3389/fimmu.2022.999163. eCollection 2022. Front Immunol. 2022. PMID: 36275657 Free PMC article.
Reg3α concentrations at day of allogeneic stem cell transplantation predict outcome and correlate with early antibiotic use.
Weber D, Weber M, Meedt E, Ghimire S, Wolff D, Edinger M, Poeck H, Hiergeist A, Gessner A, Ayuk F, Roesler W, Wölfl M, Kraus S, Zeiser R, Bertrand H, Bader P, Ullrich E, Eder M, Gleich S, Young R, Herr W, Levine JE, Ferrara JLM, Holler E. Weber D, et al. Among authors: eder m. Blood Adv. 2023 Apr 11;7(7):1326-1335. doi: 10.1182/bloodadvances.2022008480. Blood Adv. 2023. PMID: 36350750 Free PMC article.
Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD.
Akahoshi Y, Spyrou N, Hogan WJ, Ayuk F, DeFilipp Z, Weber D, Choe HK, Hexner EO, Rösler W, Etra AM, Sandhu K, Yanik GA, Chanswangphuwana C, Kitko CL, Reshef R, Kraus S, Wölfl M, Eder M, Bertrand H, Qayed M, Merli P, Grupp SA, Aguayo-Hiraldo P, Schechter T, Ullrich E, Baez J, Beheshti R, Gleich S, Kowalyk S, Morales G, Young R, Kwon D, Nakamura R, Levine JE, Ferrara JLM, Chen YB. Akahoshi Y, et al. Among authors: eder m. Blood Adv. 2023 Aug 22;7(16):4479-4491. doi: 10.1182/bloodadvances.2023009885. Blood Adv. 2023. PMID: 37315175 Free PMC article.
757 results